Table 2. Tests sensitivity and specificity.
Results are compared with those of the ELISA test. US diagnosis was used as the gold standard. Significant differences are indicated in bold.
| Test | N (%) positive in CE group | Overall sensitivity | N (%) positive in Control group | Overall specificity | Chi2 and p-value compared to ELISA | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chi2 and p-value compared to ELISA within CE group | (95%CI) | Chi2 and p-value compared to ELISA within Control group | (95% CI) | |||||||
| Active | Inactive | |||||||||
| CE1 | CE2 | CE3a | CE3b | CE4 | CE5 | |||||
| VIRapid | 43 (74.1%) | 74.1% (61.0–84.7) | 1 (96%) | 96% (79.6–99.9) | χ2 = 0.69; p = 0.405 | |||||
| 33 (89.2% [74.6–97.0]) χ2 = 0.00; p = 1.000 | 10 (47.6% [25.7–70.2]) χ2 = 1.00; p = 0.317 | 1 (96% [79.6–99.9]) χ2 = 0.00; p = 1.000 | - | |||||||
| 4 (66.7%) | 8 (88.9%) | 8 (100%) | 13 (92.9%) | 5 (50%) | 5 (50%) | - | - | |||
| DIGFA | 43 (72.9%) | 72.9% (59.7–83.6) | 7 (72%) | 72% (50.6–87.9) | χ2 = 4.00; p = 0.045 | |||||
| 34 (89.5% [75.2–97.1]) χ2 = 0.00; p = 1.000 | 9 (42.9% [21.8–66.0]) χ2 = 0.50; p = 0.479 | 7 (72% [50.6–87.9]) χ2 = 6.00; p = 0.014 | - | |||||||
| 5 (71.4%) | 9 (100%) | 8 (100%) | 12 (85.7%) | 6 (60%) | 3 (27.3%) | - | - | |||
| ADAMU-CE | 34 (57.6%) | 57.6% (44.1–70.4) | 0 (100%) | 100% (86.3–100) | χ2 = 3.20; p = 0.074 | |||||
| 27 (71.1% [54.1–84.6]) χ2 = 5.44; p = 0.019 | 7 (33.3% [14.6–57.0]) χ2 = 0.00; p = 1.000 | 0 (100% [86.3–100]) χ2 = 1.00; p = 0.317 | - | |||||||
| 4 (57.1%) | 7 (77.8%) | 7 (87.5%) | 9 (64.3%) | 3 (30%) | 4 (36.4%) | - | - | |||
| ELISA (reference test) | 41 (69.5%) | 69.5% (56.1–80.8) | 1 (96%) | 96% (79.6–99.9) | - | |||||
| 34 (89.5% [75.2–97.1]) | 7 (33.3% [14.6–57.0]) - | 1 (96% [79.6–99.9]) - | - | |||||||
| 6 (85.7%) | 8 (88.9%) | 8 (100%) | 12 (85.7%) | 5 (50%) | 2 (18.2%) | - | - | |||